CONTENTS:
- Enhancing engagement in hepatitis C care among people who inject drugs [Editorial]. Marshall A.D., Madden A., Treloar C., p. 2104-2106.
- Supervised consumption sites: a nuanced assessment of the causal evidence [Addiction opinion and debate]. Caulkins J.P., Pardo B., Kilmer B., p. 2109-2115.
- How much do we need to know about supervised consumption sites? It depends who's asking. Satel S., p. 2116-2117.
- The need to broaden and strengthen the evidence base for supervised consumption sites. May T., Holloway K., Bennett T., p. 2117-2118.
- The unmaking of 'evil': claiming space for rational discourse on US drug policy. Frydl K.J., p. 2119-2120.
- The benefits of evaluating literatures with essays. Caulkins J.P., Pardo B., Kilmer B., p. 2120-2121.
- Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Chan B., Freeman M., Kondo K., Ayers C., Montgomery J., Paynter R., et al., p. 2122-2136.
- Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. Zhang J.J.Q., Fong K.N.K., Ouyang R.G., Siu A.M.H., Kranz G.S., p. 2137-2149.
- Changes in associations of prescription opioid use disorder and illegal behaviors among adults in the United States from 2002 to 20. Mintz C.M., Hartz S.M., Borodovsky J.T., Bierut L.J., Grucza R.A., p. 2150-2159.
- Commentary on Mintz et al. (2019): Unintended or intended? Coming to grips with the opioid crisis. Dart R.C., p. 2160-2161.
- Associations between young adult marijuana outcomes and availability of medical marijuana dispensaries and storefront signage. Shih R.A., Rodriguez A., Parast L., Pedersen E.R., Tucker J.S., Troxel W.M., et al., p. 2162-2170.
- Commentary on Shih et al. (2019): Lessons from alcohol outlet availability. Wilkinson C., p. 2171-2172.
- Trajectories of injection drug use among people who use drugs in Vancouver, Canada, 1996-2017: growth mixture modeling using data from prospective cohort studies. Dong H., Hayashi K., Singer J., Milloy M.J., DeBeck K., Wood E., et al., p. 2173-2186.
- Risky driving behaviours among stimulant drug users and the role of aggression: findings from a national survey. Hayley A.C., Hart C.L., O'Malley K.Y., Stough C.K.K., Downey L.A., p. 2187-2196.
- Perceived relative harm of using e-cigarettes predicts future product switching among US adult cigarette and e-cigarette dual users. Persoskie A., O'Brien E.K., Poonai K., p. 2197-2205.
- Cost-effectiveness of population-level proactive tobacco cessation outreach among socio-economically disadvantaged smokers: evaluation of a randomized control trial. Thao V., Nyman J.A., Nelson D.B., Joseph A.M., Clothier B., Hammett P.J., et al., p. 2206-2216.
- Schizophrenia is associated with increased risk of subsequent substance abuse diagnosis: A nation-wide population-based register study. Petersen S.M., Toftdahl N.G., Nordentoft M., Hjorthoj C., p. 2217-2226.
- Commentary on Petersen et al. (2019): Development of problematic substance use in the years that follow diagnosis of schizophrenia. Lappin J.M., p. 2227-2228.
- Genetic and environmental risk factors in the non-medical use of over-the-counter or prescribed analgesics, and their relationship to major classes of licit and illicit substance use and misuse in a population-based sample of young adult twins. Gillespie N.A., Bates T.C., Hickie I.B., Medland S.E., Verhulst B., Kirkpatrick R.M., et al., p. 2229-2240.
- Association between experience of racial discrimination and hazardous alcohol use among Maori in Aotearoa New Zealand. Winter T., Riordan B.C., Surace A., Scarf D., p. 2241-2246.
- Comparison of e-cigarette use characteristics between exclusive e-cigarette users and dual e-cigarette and conventional cigarette users: an on-line survey in France. Berlin I., Nalpas B., Targhetta R., Perney P., p. 2247-2251.
- Assessment of the accuracy of salivary cotinine readings from NicAlert strips against a liquid chromatography tandem mass spectrometry assay in self-reported non-smokers who passed carbon monoxide but failed NicAlert validation. Etter J.F., p. 2252-2256.
- Adding quality to quantity in randomized controlled trials of addiction prevention and treatment: a new framework to facilitate the integration of qualitative research. Maher L., Neale J., p. 2257-2266.
- Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Barbosa C., Fraser H., Hoerger T.J., Leib A., Havens J.R., Young A., et al., p. 2267-2278.
- Commentary on Barbosa et al. (2019): The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs. Schackman B.R., Meisel Z.F., p. 2279-2280.